检索结果 - Meredith Libeg

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy 由 Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy 由 Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Shenghui Tang, Meredith Libeg, Paul G. Kluetz, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma 由 Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: